- Research article
- Open Access
- Open Peer Review
Evaluation of the association between the common E469K polymorphism in the ICAM-1 gene and diabetic nephropathy among type 1 diabetic patients in GoKinD population
BMC Medical Geneticsvolume 9, Article number: 47 (2008)
The ICAM-1 gene is a strong positional and biological candidate for susceptibility to the development of T1D and DN. We have recently demonstrated that SNP rs5498(E469K) confers susceptibility to the development of T1D and might be associated with DN in Swedish Caucasians. The present study aimed to further evaluate the association between the ICAM-1 genetic polymorphisms and DN.
Two common non-synonymous SNPs, including rs5498(E469K) and rs1799969(R241G), in the ICAM-1 gene were genotyped in 662 (312 female/350 male) T1D patients with DN and 620 (369/251) without DN. All patients were selected from the GoKinD study.
Genotype distributions of both SNPs were in Hardy-Weinberg equilibrium but SNP rs5498(E469K) had high heterozygous index. In this SNP, the heterozygosity and positivity for the allele G were found to be significantly associated with DN in female T1D patients (P = 0.010, OR = 0.633, CI 95% 0.447–0.895 and P = 0.026, OR = 0.692, CI 95% 0.500–0.958). Furthermore, the female patients without DN carrying three genotypes A/A, A/G and G/G had different cystatin levels (0.79 ± 0.17, 0.81 ± 0.14 and 0.75 ± 0.12 mg/L, P = 0.021). No significant association of SNP rs1799969 (R241G) with DN was found.
The present study provides further evidence that SNP rs5498(E469K) in the ICAM-1 gene presents a high heterozygous index and the allele G of this polymorphism may confers the decreased risk susceptibility to the development of DN in female T1D patients among the GoKinD population.
Genome-wide scans and linkage analyses have predicted that the susceptibility gene(s) for type 1 diabetes (T1D) and diabetic nephropathy (DN) reside in chromosome 19p13 [1–3]. The intercellular adhesion molecule-1 (ICAM-1) gene is located in this chromosomal region. ICAM-1 is a 90-kD cell surface glycoprotein of the Ig super family involved in the firm attachment of leukocytes to endothelium [4, 5]. Expression of ICAM-1 can be induced by multiple factors, including inflammatory cytokines, reactive oxygen species and shear stress [6, 7]. Normally, ICAM-1 is expressed at low levels on the surface of arterial endothelial cells, but the expression at both mRNA and protein levels are significantly increased in animal models of diabetic nephropathy with T1D [7–9] and T2D [10–12]. Furthermore, clinical evidence indicates that the levels of plasma adhesion molecule are elevated in T1D patients . Therefore, the ICAM-1 gene is considered as a strong positional and biological candidate for the susceptibility to the development of T1D and DN.
In the recent years, several genetic association studies concerning two common non-synonymous SNPs, including rs5498 E469K(A/G) and rs1799969 R241G(G/A), in the ICAM-1 gene in T1D patients have been reported. The G allele of SNP rs5498 E469K(A/G) was preferentially transmitted the affected offspring among Romanian T1D families . This polymorphism was subsequently found to be associated with adult-onset T1D patients in Japanese . However, the association of this SNP with T1D was not detectable in Danish, Finnish and British Caucasians [16, 17]. In another SNP R241G(G/A), transmission of the allele G was also preferentially transmitted to the affected offspring among T1D families in Finnish, British, Romanian, European and American Caucasians . We have recently conducted a genetic association study of five SNPs in the ICAM-1 gene among Swedish non-diabetic subjects, T1D patients with and without DN . Data indicate that SNP rs5498 E469K(A/G) is associated with T1D in Swedish population. The frequency of the major A allele of this SNP is increased gradually from non-diabetic controls, to T1D patients without DN and to the patients with DN, which suggests that this SNP might be associated with DN. In order to further evaluate the susceptibility of the ICAM-1 genetic polymorphisms in the development of DN, in the present study, we have focused on genetic association analyses of two common non-synonymous SNPs i.e. rs5498 E469K(A/G) and rs1799969 R241G(G/A) in the ICAM-1 gene by using the well-selected and characterized cohort of T1D patients with and without DN from the Genetics of Kidneys in Diabetes (GoKinD) study .
Clinical material employed in the present study includes a cohort of 1282 (female 681/male 601) T1D patients. They were selected from the GoKinD study and collected by the Juvenile Diabetes Research Foundation in collaboration with the Joslin Diabetes Center and George Washington University, and the United States Centers for Diabetes Control and Prevention . The patients with T1D were diagnosed before age 31 years old and the duration of T1D is more than 10 years. Medical treatment with insulin for the patients was instituted within one year of diagnosis, and was uninterrupted since then.
In total, 620 patients (369/251) without DN were used as the controls and 662 (312/350) with DN as the cases. Among the patients, 1177 (91.8%) were of European descent, while 105 (8.2%) patients were Americans of Black, Asian, Hispanic or Indian descent. The patients with DN had T1D for at least 10 years and had persistent proteinuria or ESRD (not due to condition other than diabetes). Persistent proteinuria was defined as 2 out of 3 tests positive for albuminuria (at least 1 month apart), i.e. dipstick (Albustix or Multistix) at least 1+ or Urine Albumin/Urine Creatinine Ratio (ACR) value exceeding 300 μg albumin/mg of urine creatinine. The patients without DN had persistent normalbuminuria despite duration of T1D for at least 15 years and had never been treated with ACE inhibitors. Persistent normoalbuminuria was defined as at least 2 out 3 of ACR measurements (at least 1 month apart) in random urine specimens being less than 20 μg albumin/mg of urine creatinine. If 3 ACR measurements were needed, the highest must also be less than 40 μg albumin/mg of urine creatinine. ESRD is recognized as the patients need chronic dialysis or kidney transplant treatment to maintain their life. The onset of ESRD is defined as the date of the first dialysis or kidney transplant, whichever occurred first. Other kidney diseases in cases were excluded .
Individuals were excluded from the study if they did not meet the inclusion criteria just described or if any of the following exclusion criteria were met: Unable or unwilling to give informed consent; Unable to communicate with staff; Major psychiatric disorder such as schizophrenia; Exclusion in relation to medication: Any antihypertensive medication for controls; Infectious disease: self-reported HIV positive and active tuberculosis; Pregnant women (although they may be reconsidered 3 months after delivery); Other kidney disease due to condition other than diabetes.
The cases and controls selected from the GoKinD study were T1D patients with the severity of DN and T1D patients without DN. T1D patients with micro-albuminuria were not included. The GoKinD study was approved by the local ethics committees. Material and data transfer agreement (MTA) was made prior to the present study. The clinical characteristics of the patients are presented in Table 1.
SNPs selection and genotyping
In the present study, we selected two non-synonymous SNPs, rs1799969 R241G and rs5498 E469K(A/G) for genotyping . These two polymorphisms are located, respectively, in exons 4 and 6 of the ICAM-1 gene. The SNP ID numbers and detailed sequence information are available in the public SNP database  Genomic DNA samples were supplied from the GoKinD study. Genotyping experiments were performed using a high-throughput SNP scoring technique called dynamic allele specific hybridization (DASH). PCR-DASH assays and genotyping protocols are described in our previous report .
Allele frequency and genotype distribution of the studied SNPs were tested for Hardy-Weinberg equilibrium (HWE). For differences between T1D patients with DN (the cases) and without DN (the controls), two models were tested comparing either allele frequencies in 2 × 2 contingency tables or genotypes in 3 × 2 contingency tables. The models were further used for testing either heterozygosity (22 vs 12) or allele positivity (11+12 vs 22). Odds ratios (OR) and 95% confidence intervals (CI) were calculated to test for relative risk for association. P-values less than 0.05 were interpreted as statistically significant. Statistical powers were calculated using software of PowerSampleSize (PS version 2.1.31) . Tests for association between genotypes and quantitative traits were performed using Kruskal-Wallis analysis of ranks for traits with non-normal distributions, or alternatively, ANOVA for normally distributed traits. Normal probability plots were created and parameter distributions were transformed to natural logarithm when needed to improve the skew-ness and for obtaining a normal distribution before performing statistical analysis of the relevant phenotypes. All statistical analyses were performed using Statistica version 7.1 (StatSoft Inc. Tulsa, USA) and/or BioMedical Data Program (BMDP) version 1.12 (Los Angeles, USA).
We have genotyped SNPs rs1799969 R241G and rs5498 E469K in the ICAM-1 gene with the GoKinD material. For genotyping quality control, DNA samples of the patients with or without DN were distributed randomly across plates, and negative controls (water blanks) were included in each plate. Successful genotype calls in all samples were ≥95%, and the plates were randomly genotyped twice for duplication. The accuracy was calculated to be 98%. Genotype distribution in both was in HWE (P > 0.05).
We first examined the allelic association of SNPs rs1799969 R241G and rs5498 E469K in the ICAM-1 gene with DN in the GoKinD population. The frequencies of minor alleles in these two polymorphisms were similar between the groups of T1D patients with and without DN (Table 2). In SNP rs5498 E469K, the G allele frequency in the patients without DN was 46.0%, which was not significantly different from the frequency in the patients with DN (44.8%, P = 0.554). In SNP rs1799969 R241G, the A allele frequencies were 11.5% in T1D patients without DN and 10.3% in the patients with DN (P = 0.325). We further analyzed the heterozygosity and allele positivity of these two SNPs, and found that rs5498 E469K had high heterozygous index, and the difference of heterozygous frequencies between T1D patients with and without DN was borderline significant (P = 0.052). We found that the frequency of major allele A in female T1D with DN was similar to the frequency in female patients without DN (57.2% vs 54.2%, P = 0.265). The association of heterozygosity and allele G positivity between T1D patients with and without DN in females was found to be significant (P = 0.010, OR = 0.633, CI 95% 0.447–0.895 and P = 0.026, OR = 0.692, CI 95% 0.500–0.958, respectively), but not in males (P = 0.766 and 0.853). In the analyses, statistical power was calculated with number of patients, type 1 error probability for a two-sided test, relative risk of the control treatment relative to the experimental treatment and ratio of control to experiment patients, and the power reached to 0.9. In SNP rs1799969 R241G, there was no high heterozygous index in the genotype distribution. Analyses of allelic frequencies and genotype distributions in this polymorphism between the patients with and without DN in females, males or both sexes were performed and no significant association was found.
We attempted to detect the association between phenotypes and genotypes of SNP rs5498 E469K in the female T1D patients without DN or with DN. We found no significant difference in clinical features among female T1D patients with DN carrying three different genotypes, although the patients with DN and genotype A/G had slightly increased diastolic blood pressure in comparison with the patients with homozygous genotypes A/A and G/G (74 ± 11 vs 71 ± 11, 71 ± 11 mmHg, P = 0.063, Table 3). Among the female T1D patients without DN carrying genotypes A/A, A/G and G/G, however, there were significant differences in cystatin levels (0.79 ± 0.17, 0.81 ± 0.14 and 0.75 ± 0.12 mg/L, P = 0.021).
In the present study, we have genotyped two non-synonymous SNPs rs1799969 R241G and rs5498 E469K in the ICAM-1 gene in a relatively large cohort from the GoKinD study. This cohort consists of the cases of T1D patients with severity of DN and the controls of T1D patients without DN. Data indicated that SNP rs5498 E469K presented a high heterozygous index in the genotype distribution of this GoKinD population. The observation is consistent with the previous and our recent studies in Danish, Finnish, Japanese and Swedish populations (See the summary, 19). Interestingly, we found that the major allele A in SNP rs5498 E469K was increased from T1D patients without DN to the patients with DN in females of the GoKinD population. Further analyses of heterozygosity and allele positivity indicated that the minor allele G of this SNP was associated with decreased risk susceptibility to the development of DN in female T1D patients. In our previous study using Swedish material , the gradually increasing of the major allele A of this polymorphism from non-diabetic subjects, to T1D patients without DN and to the patients with DN was observed. The association between this polymorphism and DN was not detected most likely due to limited size of samples.
We have attempted to detect the association of phenotypes according to the genotypes of this SNP in T1D patients with DN. We found no significant difference in clinical features among female T1D patients with DN carrying three different genotypes. Among the female patients without DN, however, the carriers with heterozygosity had significantly increased serum cystatin levels than the patients with heterozygosity. The data indicate that the heterozygosity of SNP rs5498 E469K may play a role in the development of DN. The previous studies demonstrate that the allele A of SNP rs5498 E469K is increased in T1D patients compared to non-diabetic subjects [14, 15, 19]. In the present study, we found that the allele G of this SNP is associated with the decreased risk susceptibility in female T1D patients with DN. Question concerning the gender specificity of genetic influence of the ICAM-1 genetic variation is then taken into our consideration. Beyond this study, we have recently studied several candidate genes, including NPY and AdipoQ in T1D and DN, and observed that the genetic polymorphisms in the NPY and AdipoQ genes are associated with T1D patients with DN in females but not in males [23, 24]. However, we can't simply make a conclusion because our knowledge needs to be improved based upon accumulation of evidence from genetic studies and clinical observation in relation to gender specificity of DN.
rs1799969 R241G(G/A) is another non-synonymous polymorphism in the ICAM-1 gene and its genotype distribution has no high heterozygous index in the GoKinD population. Previous reports demonstrate that the allele G of this SNP is transmitted in T1D families among Finnish, British, Romanian, European and American Caucasians . But, this polymorphism is not associated with DN among T1D patients in either Swedish  or GoKinD populations. A recent study has indicated that SNP rs5498 E469K but not rs1799969 R241G in the ICAM-1 gene is associated with the development of differentiation syndrome in actue promyelocytic leukemia . Taking together with our study and the recent report, we suggest that SNP rs1799969 R241G may not be the major defect in the development of DN.
In conclusion, we have evaluated the association between the ICAM-1 genetic polymorphisms and DN with the material from the GoKinD study and provided evidence that SNP E469K but not R249G is associated with DN in T1D. The allele G of SNP E469K in the ICAM-1 gene may confer the decreased risk susceptibility to the development of DN in female T1D patients.
the Genetics of Kidneys in Diabetes study
intercellular adhesion molecule-1
single nucleotide polymorphism
type 1 diabetes.
Cox NJ, Wapelhorst B, Morrison VA, et al: Seven regions of the genome show evidence of linkage to type 1 diabetes in a consensus analysis of 767 multiplex families. Am J Hum Genet. 2001, 69 (4): 820-30. 10.1086/323501.
Mein CA, Esposito L, Dunn MG, et al: A search for type 1 diabetes susceptibility genes in families from the United Kingdom. Nat Genet. 1998, 19 (3): 297-300. 10.1038/991.
Pollin TI, Hsueh WC, Steinle NI, et al: A genome-wide scan of serum lipid levels in the Old Order Amish. Atherosclerosis. 2004, 173 (1): 89-96. 10.1016/j.atherosclerosis.2003.11.012.
Staunton DE, Marlin SD, Stratowa C, et al: Primary structure of ICAM-1 demonstrates interaction between members of the immunoglobulin and integrin supergene families. Cell. 1988, 52 (6): 925-33. 10.1016/0092-8674(88)90434-5.
Stolpe A, Saag PT: Intercellular adhesion molecule-1. J Mol Med. 1996, 74 (1): 13-33. 10.1007/BF00202069.
Miyatake N, Shikata K, Sugimoto H, et al: Intercellular adhesion molecule 1 mediates mononuclear cell infiltration into rat glomeruli after renal ablation. Nephron. 1998, 79 (1): 91-8. 10.1159/000044997.
Sugimoto H, Shikata K, Hirata K, et al: Increased expression of intercellular adhesion molecule-1 (ICAM-1) in diabetic rat glomeruli: glomerular hyperfiltration is a potential mechanism of ICAM-1 upregulation. Diabetes. 1997, 46 (12): 2075-81. 10.2337/diabetes.46.12.2075.
Okada S, Shikata K, Matsuda M, et al: Intercellular adhesion molecule-1-deficient mice are resistant against renal injury after induction of diabetes. Diabetes. 2003, 52 (10): 2586-93. 10.2337/diabetes.52.10.2586.
Qi XM, Wu GZ, Wu YG, et al: Renoprotective effect of breviscapine through suppression of renal macrophage recruitment in streptozotocin-induced diabetic rats. Nephron Exp Nephrol. 2006, 104 (4): e147-57. 10.1159/000094966.
Chow FY, Nikolic-Paterson DJ, Ozols E, et al: Intercellular adhesion molecule-1 deficiency is protective against nephropathy in type 2 diabetic db/db mice. J Am Soc Nephrol. 2005, 16 (6): 1711-22. 10.1681/ASN.2004070612.
Coimbra TM, Janssen U, Grone HJ, et al: Early events leading to renal injury in obese Zucker (fatty) rats with type II diabetes. Kidney Int. 2000, 57 (1): 167-82. 10.1046/j.1523-1755.2000.00836.x.
Matsui H, Suzuki M, Tsukuda R, et al: Expressf ICAM-1 on glomeruli is associated with progression of diabetic nephropathy in a genetically obese diabetic rat, Wistar fatty. Diabetes Res Clin Pract. 1996, 32 (1–2): 1-9. 10.1016/0168-8227(96)01209-0.
Nelson CL, Karschimkus CS, Dragicevic G, et al: Systemic and vascular inflammation is elevated in early IgA and type 1 diabetic nephropathies and relates to vascular disease risk factors and renal function. Nephrol Dial Transplant. 2005, 20 (11): 2420-6. 10.1093/ndt/gfi067.
Guja C, Todd JA, Welsh K, et al: Incraesed transmission of intercellular adhesion-molecule-1 469E allele in type 1 Romanian diabetic families. Diabetologia. 1999, 42 (Suppl 1): 327-327.
Nishimura M, Obayashi H, Maruya E, et al: Association between type 1 diabetes age-at-onset and intercellular adhesion molecule-1 (ICAM-1) gene polymorphism. Hum Immunol. 2000, 61 (5): 507-10. 10.1016/S0198-8859(00)00101-4.
Kristiansen OP, Nolsoe RL, Holst H, et al: The intercellular adhesion molecule-1 K469E polymorphism in type 1 diabetes. Immunogenetics. 2000, 52 (1–2): 107-11. 10.1007/s002510000258.
Nejentsev S, Laine AP, Simell O, et al: Intercellular adhesion molecule-1 (ICAM-1) K469E polymorphism: no association with type 1 diabetes among Finns. Tissue Antigens. 2000, 55 (6): 568-70. 10.1034/j.1399-0039.2000.550608.x.
Nejentsev S, Guja C, McCormack R, et al: Association of intercellular adhesion molecule-1 gene with type 1 diabetes. Lancet. 2003, 362 (9397): 1723-4. 10.1016/S0140-6736(03)14847-7.
Ma J, Mollsten A, Prazny M, et al: Genetic influences of the intercellular adhesion molecule 1 (ICAM-1) gene polymorphisms in development of Type 1 diabetes and diabetic nephropathy. Diabet Med. 2006, 23 (10): 1093-9. 10.1111/j.1464-5491.2006.01948.x.
Mueller PW, Rogus JJ, Cleary PA, et al: Genetics of Kidneys in Diabetes (GoKinD) study: a genetics collection available for identifying genetic susceptibility factors for diabetic nephropathy in type 1 diabetes. J Am Soc Nephrol. 2006, 17 (7): 1782-90. 10.1681/ASN.2005080822.
Ma J, Nordman S, Möllsten A, et al: Distribution of neuropeptide Y Leu7Pro polymorphism in the patients with type 1 diabetes and diabetic nephropathy among Swedish and American populations. Euro J Endocrin. 2007, 157: 641-5. 10.1530/EJE-07-0354.
Zhang DY, Ma J, Brismar K, et al: A single nucleotide polymorphism alters the sequence of SP1 binding site in the adiponectin promoter region and associates with diabetic nephropathy among the GoKinD type 1 diabetic patients. J Diabetes Complications. 2008 in press.
Dore AI, Santana-Lemos BA, Coser VM, et al: The association of ICAM-1 exon 6 (E469K) but not of ICAM-1 exon 4 (G241R) and PECAM-1 exon 3 (L125V) polymorphisms with the development of differentiation syndrome in acute promyelocytic leukemia. J Leukoc Biol. 2007, 82: 1-4. 10.1189/jlb.0207095.
The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2350/9/47/prepub
The authors thank all subjects for participating in the present study. The sample collection and the GoKinD study were supported by the Juvenile Diabetes Research Foundation in collaboration with the Joslin Diabetes Center and George Washington University, and by the United States Centers for Diabetes Control and Prevention. The present work was supported by Novo Nordic Consortium, Swedish Research Council, Family Erling-Persson foundation, Novo Nordisk Scandinavia, Loo and Hans Osterman foundation and Swedish Diabetes Association. Jun Ma is originally from Weifang Medical University and Dongying Zhang from Chongqing Medical University, China.
The authors declare that they have no competing interests.
JM carried out the molecular genetic studies and data analysis. DZ assisted with experiments and data analysis. KB, SE and HFG conceived of the study and also evaluated the data. HFG drafted the manuscript. All authors participated in the study design and coordination. All authors read and approved the final version of manuscript.
Authors’ original submitted files for images
Below are the links to the authors’ original submitted files for images.